The Claim
Among adults with overweight or obesity, cardiovascular disease, and no diabetes who have baseline estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m², treatment with once-weekly semaglutide 2.4 mg is likely to result in a greater increase in eGFR of 2.19 ml/min/1.73m² at 104 weeks compared to placebo, indicating a potentially enhanced kidney benefit in individuals with early-stage chronic kidney disease.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults who are overweight, have heart disease, and early kidney problems but not diabetes, taking a weekly semaglutide shot might help their kidneys work better over two years compared to a placebo.
See the scientific wording
Among adults with overweight or obesity, cardiovascular disease, and no diabetes who have baseline eGFR <60 ml/min/1.73m², once-weekly semaglutide 2.4 mg likely results in a greater increase in eGFR by 2.19 ml/min/1.73m² at 104 weeks compared to placebo, suggesting a more pronounced kidney benefit in those with early-stage chronic kidney disease.
What the research says
1 studyStudy: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study found that people with early kidney issues who took semaglutide had their kidney function improve more than those who took a placebo, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.